News Search Results
Feb 10, 2026, 08:30 ET Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
looking to refresh aging CNS pipelines. A single successful NSA platform can support multiple indications, creating built-in expansion opportunities and upside optionality. As mental health remains a top global healthcare priority and capital continues flowing into differentiated CNS assets, NSAs are increasingly
More news about: Market News Updates
Feb 10, 2026, 08:00 ET Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd.
products in several therapeutic areas including anti-infectives, pain, CNS disorders, cardiovascular diseases and gastroenterology. Shionogi's research and development currently target two therapeutic areas: infectious diseases and pain/CNS disorders. For more information on Shionogi & Co., Ltd., please
More news about: Cumulus Neuroscience
Feb 10, 2026, 08:00 ET Stellaromics Appoints Industry Veterans Stacie Weninger and Steve McPhail to Board of Directors
application. With more than 20 years of experience building and advising neuroscience companies, her unique understanding of central nervous system (CNS) disorders, and their nuances, will be invaluable as Stellaromics addresses the most challenging questions in disease pathology.Steve McPhail
More news about: Stellaromics
Feb 10, 2026, 07:00 ET Corero Network Security and EdgeUno Partner to Scale Real-Time, Automated DDoS Protection Across Latin America
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, today announced a strategic partnership
More news about: Corero Network Security
Feb 09, 2026, 16:05 ET REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II
iduronate-2-sulfatase (IDS) gene to the CNS. Delivery of the IDS gene within cells in the CNS could provide a permanent source of secreted iduronate-2-sulfatase (I2S) protein beyond the blood-brain barrier, allowing for long-term cross correction of cells throughout the CNS. RGX-121 expressed protein is
More news about: REGENXBIO Inc.
Feb 09, 2026, 11:14 ET Lunai Bioworks, Inc. Issues Letter to Shareholders
therapies reach patients faster. We have established new fully owned company technologies for royalty-based partnerships. While we have been focused on CNS diseases today, we launched a new AI oncology pilot with a clinical-stage partner using our Augusta platform to re-analyze data from a randomized Phase
More news about: Lunai Bioworks Inc.
Feb 09, 2026, 08:18 ET EQT Life Sciences co-leads USD 39 million Series A in Aerska to help systematically deliver RNA medicines to the brain
proprietary "brain shuttle" technology to overcome the blood-brain barrier, a fundamental challenge that has historically limited RNA therapeutics in CNS diseases. This delivery approach is designed to enable intravenous or subcutaneous administration, achieving uniform and deep brain distribution with
More news about: EQT
Feb 09, 2026, 08:16 ET EQT Life Sciences co-leads USD 39 million Series A in Aerska to help systematically deliver RNA medicines to the brain
proprietary "brain shuttle" technology to overcome the blood-brain barrier, a fundamental challenge that has historically limited RNA therapeutics in CNS diseases. This delivery approach is designed to enable intravenous or subcutaneous administration, achieving uniform and deep brain distribution with
More news about: EQT
Feb 09, 2026, 06:55 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for January 2026
NEW YORK, Feb. 9, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $93.1 billion as of January 31, 2026, an increase of $2.5 billion from assets under management
More news about: Cohen & Steers, Inc.
Feb 05, 2026, 08:00 ET Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications
predicted human efficacious dose, with high potential in multiple indications including autoimmune and chronic cardiometabolic diseases with no obvious CNS (central nervous system) related toxicity observed in preclinical studies.HONG KONG, Feb.
More news about: Insilico Medicine
Feb 04, 2026, 08:44 ET Allergy Research Group Announces Peer-Reviewed Publication Advancing Thyroid and Endocrine Integration Science
International Journal of Molecular Sciences. The paper, "Energy Allocation Resilience and Endocrine Integration," is led by Dr. Corey Schuler, DC, MS, CNS, LN, Director of Medical Affairs at Allergy Research Group, with contributions from members of ARG's Medical Affairs Team and Scientific Advisory Board,
More news about: Allergy Research Group
Feb 03, 2026, 10:47 ET Cognision Launches Cognision360™: A Unified Platform Transforming Neurobiomarker Acquisition, Processing, and Analysis in CNS Clinical Trials
data streams into a single, standardized system—addressing one of the pharmaceutical industry's most persistent challenges in central nervous system (CNS) drug development.
More news about: Cognision
Feb 02, 2026, 08:25 ET Mwyngil Therapeutics Announces Updates on NLRP3 Portfolio
disorders.BT-409 is an orally administered small-molecule designed to selectively inhibit the NLRP3 inflammasome with demonstrated central nervous system (CNS) penetration. Preclinical studies support its potential to directly modulate neuroinflammation within the brain, differentiating it from peripherally
More news about: Mwyngil Therapeutics
Jan 29, 2026, 19:01 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX
therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The press release also disclosed that "[t]he FDA also placed a clinical hold on RGX-121, for
More news about: Pomerantz LLP
Jan 29, 2026, 16:46 ET Myosin Therapeutics Invited to Present at Biocom California's Global Partnering & Investor Conference
TherapeuticsMyosin Therapeutics is a biotechnology company based in Jupiter, Florida, developing first-in-class therapies for oncology and CNS disorders by targeting molecular nanomotor proteins. The company's lead program, MT-125, is being developed for glioblastoma as the lead indication within
More news about: Myosin Therapeutics Inc.
Jan 29, 2026, 10:06 ET Sprout Pharmaceuticals' Addyi® (flibanserin) Named "Best Prescription for Low Libido" in the 2026 Oprah Daily Menopause O-wards
increase the risk of hypotension and syncope.Central Nervous System (CNS) Depression (e.g., Somnolence, Sedation): Can occur with ADDYI alone and is exacerbated by other CNS depressants. The risk of CNS depression is also increased if ADDYI is taken during waking hours. Patients should
More news about: Sprout Pharmaceuticals
Jan 29, 2026, 07:00 ET Corero Network Security Secures Two Tier-1 APAC Telecommunications Wins
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, today announced two significant wins
More news about: Corero Network Security
Jan 29, 2026, 07:00 ET Hope Rising in Hainan: International NUT Carcinoma Center Launches in Boao
includes peripheral TYK2 (JH2) inhibitor for moderate-to-severe plaque psoriasis currently in Phase III trials, and central TYK2 (JH2) inhibitor for CNS diseases in Phase I trials. With a rich and innovative pipeline targeting numerous current refractory and incurable diseases, the company is dedicated
More news about: Zhejiang Wenda Pharma Technology Co., Ltd.
Jan 29, 2026, 04:00 ET LifeArc Ventures 2025: New geographies and investments, a growing team and continued portfolio progress
diverse array of therapeutic modalities and technologies, in particular areas with significant unmet needs such as autoimmune diseases, fibrosis and CNS disorders.GlycoEra AG's $130 million Series B: LifeArc Ventures joined Novo Holdings, Catalio Capital Management, QIA,
More news about: LifeArc
Jan 28, 2026, 22:31 ET Corero Network Security Mendapatkan Dua Kontrak Dengan Perusahaan Telekomunikasi Terkemuka di Asia Pasifik
Corero Network Security (AIM: CNS) (OTCQX: DDOSF) adalah pemimpin yang diakui di bidang DDoS protection maupun ketersediaan layanan di waktu nyata dan dapat disesuaikan. Hari ini Corero
More news about: Corero Network Security
Jan 28, 2026, 19:00 ET Corero Network Security Chốt Hợp Đồng với 2 Nhà Khai Thác Viễn Thông Cấp 1 tại Khu Vực Châu Á - Thái Bình Dương (APAC).
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), công ty hàng đầu được công nhận trong lĩnh vực bảo vệ chống tấn công từ chối dịch vụ phân tán (DDoS) và là đơn vị tiên phong cung cấp
More news about: Corero Network Security
Jan 28, 2026, 16:16 ET CPKC announces industry veteran Gordon Trafton appointed board vice-chair
Senior Vice-President Strategic Acquisitions and Integration and as Senior Vice-President, Southern Region at CN. Prior to that, Mr. Trafton worked as CN's Vice President, Operations Integration. On CPKC's board, Mr. Trafton chairs the Risk and Sustainability Committee, serves on the Management Resources
More news about: CPKC
Jan 28, 2026, 07:43 ET CMUH-Ever Supreme Team Develops World-First Brain-Targeting Exosome Delivering Curcumin Across the Blood-Brain Barrier for Parkinson's Disease
exosomes for solid tumors, the research team has now extended this advanced platform into the highly challenging domain of the central nervous system (CNS).
More news about: China Medical University Hospital
Jan 28, 2026, 07:30 ET REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
to the central nervous system (CNS). Delivery of the IDS gene within cells in the CNS could provide a permanent source of secreted iduronate-2-sulfatase (I2S) protein beyond the blood-brain barrier, allowing for long-term cross correction of cells throughout the CNS. RGX-121 expressed protein is
More news about: REGENXBIO Inc.
Jan 27, 2026, 17:52 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.